Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Why Ocean Power, MGT Capital and 3 Other Stocks Are Making Moves Today

Stereotaxis’ System Deployed at the University of Chicago Medicine

Shares of Stereotaxis Inc (NASDAQ:STXS) continue to gain value after the company said on Wednesday that the University of Chicago Medicine will implement its Niobe ES remote magnetic navigation system as part of a plan to create a cutting-edge arrhythmia technology suite. A press release by the St. Louis, Missouri-based company said that the Niobe system is a revolutionary invention in the field of cardiac ablation which helps treat the difficult-to-reach arrhythmias with high precision. Last week, Stereotaxis announced that the Texas Children’s Hospital in Houston also installed its Niobe ES system. Shares are up by 7% today and have soared by 33% over the past six trading sessions. Only four funds tracked by us held long positions in Stereotaxis Inc (NASDAQ:STXS) at the end of the first quarter.

Brainstorm Plunging

Brainstorm Cell Therapeutics Inc (NASDAQ:BCLI) is taking it on the chin today, nosediving by 13% so far today. Shares of the biotechnology company, which is set to announce the results of its Phase 2 Study of NurOwn in Patients with ALS on July 18, had skyrocketed by 33% on Thursday. At the end of March, three hedge funds in our system held shares of Brainstorm Cell Therapeutics Inc (NASDAQ:BCLI).

Follow Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI)
Trade (NASDAQ:BCLI) Now!

Great Basin Scientific Sinks on Preliminary Results

Great Basin Scientific Inc (NASDAQ:GBSN) has lost 17.86% of its value today following the release of its preliminary results for the second quarter of 2016. Revenue for the quarter came in at $728,957, a 38.7% increase compared to the same quarter of last year. The company added 38 new customers during the quarter, lifting its customer base to 260. It’s unclear why the market has reacted so negatively to the company’s press release, which appears to be relatively positive. No funds that we track were long Great Basin Scientific Inc (NASDAQ:GBSN) as of March 31, after John Overdeck and David Siegel’s Two Sigma Advisors sold out of their small position in the stock during the first quarter.

Follow Great Basin Scientific Inc. (NASDAQ:GBSN)
Trade (NASDAQ:GBSN) Now!

Disclosure: None